Results 51 to 60 of about 22,047 (159)

Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood.

open access: yesPLoS ONE, 2013
Apixaban is a new oral anticoagulant with a specific inhibitory action on FXa. No information is available on the reversal of the antihemostatic action of apixaban in experimental or clinical settings.
Gines Escolar   +9 more
doaj   +1 more source

Accidental apixaban intoxication in a 23-month-old child: a case report

open access: yesBMC Pediatrics, 2020
Background Direct oral anticoagulants, such as apixaban, are increasingly used in everyday practice in order to treat or prevent thromboembolic diseases. To date, there is no available data about apixaban pharmacokinetics in children, and no intoxication
Manon Launay   +4 more
doaj   +1 more source

Do We Really Know How to Manage Anticoagulated Patients for Periodontal Nonsurgical Therapy? An Observational Cohort Study

open access: yesInternational Journal of Dental Hygiene, EarlyView.
ABSTRACT Objectives The aim of this work is to assess and compare the impact of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKA) during and immediately after periodontal nonsurgical therapy. Materials and Methods A prospective observational cohort study was conducted with patients who presented a history of cardiovascular disease ...
F. Berton   +5 more
wiley   +1 more source

Zero‐Contrast Versus Contrast‐Guided Left Atrial Appendage Occlusion: A Comparative Analysis of Procedural and Long‐Term Outcomes

open access: yesJournal of Cardiovascular Electrophysiology, EarlyView.
Zero‐contrast left atrial appendage occlusion yielded high procedural success and similar periprocedural adverse event rates compared to the contrast‐guided approach. At 45‐day follow‐up, successful LAA closure (defined as peri‐device leak ≤ 5 mm) and device‐related thrombus rates were similar.
Joe Demian   +12 more
wiley   +1 more source

Cost–effectiveness and budget impact analysis of switching from apixaban to rivaroxaban treatment among patients with nonvalvular atrial fibrillation in a German healthcare setting

open access: yesJournal of Comparative Effectiveness Research
Aim: Direct oral anticoagulant (DOAC) switching often occurs in patients with nonvalvular atrial fibrillation (NVAF) formedical and nonmedical reasons. Limited data describe the economic consequences of DOAC switching in patients with NVAF.
Rupesh Subash   +9 more
doaj   +1 more source

Implementation of a Standardized Nurse‐Guided Heparinization Protocol Improves Anticoagulation During Left Atrial Ablation Procedures

open access: yesJournal of Cardiovascular Electrophysiology, EarlyView.
A standardized, nurse‐led heparinization protocol significantly improves the speed, consistency, and precision of achieving therapeutic ACT levels during left atrial ablation, while reducing excessive anticoagulation and maintaining a comparable safety profile to conventional operator‐guided dosing.
Vanessa Sciacca   +14 more
wiley   +1 more source

Comparison of Spatio‐Temporal Dispersion Electrogram Ablation and Low Voltage Zone Ablation in Patients With Persistent Atrial Fibrillation

open access: yesJournal of Cardiovascular Electrophysiology, EarlyView.
This study compared STDE‐guided versus LVZ‐guided ablation beyond PVI in 107 persistent AF patients. At 24 months, the AF‐free survival rate was significantly higher in the STDE group (76.3% vs. 58.4%, p=0.027). STDE ablation independently reduced recurrence risk (HR: 0.29, p=0.004), providing superior clinical efficacy over LVZ ablation.
Yutaro Kaneko   +6 more
wiley   +1 more source

Primary cardiovascular preventive effect of thiazolidinedione in adults with type 2 diabetes: A nationwide cohort study in Korea

open access: yesJournal of Diabetes Investigation, EarlyView.
Among Korean adults with type 2 diabetes and no prior cardiovascular disease, thiazolidinedione use was associated with a lower risk of the primary composite outcome of stroke, myocardial infarction, hospitalization for heart failure, and all‐cause mortality compared to dipeptidyl peptidase‐4 inhibitor use. ABSTRACT Background Thiazolidinediones (TZDs)
Yun Young Choi   +4 more
wiley   +1 more source

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban

open access: yesClinical Pharmacology: Advances and Applications, 2014
Charles Frost,1 Yan Song,1 Yu Chen Barrett,1 Jessie Wang,2 Janice Pursley,3 Rebecca A Boyd,4 Frank LaCreta1 1Exploratory Clinical and Translational Research, 2Exploratory Development Global Biometric Sciences, 3Analytical and Bioanalytical Development ...
Frost C   +6 more
doaj  

Acute severe renal failure in a patient receiving apixaban: a case report

open access: yesItalian Journal of Medicine
Because there is little clinical experience with apixaban in patients with severe renal impairment and non-valvular atrial fibrillation, the European Medicines Agency does not advise using it to prevent strokes in these patients.
Attilia Maria Pizzini   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy